Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia
- 1 February 2011
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1), 133-135
- https://doi.org/10.3816/clml.2011.n.030
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- How I treat Waldenström macroglobulinemiaBlood, 2009
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Bendamustine: Rebirth of an Old DrugJournal of Clinical Oncology, 2009
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)Blood, 2008
- Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent StudyJournal of Clinical Oncology, 2008
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsClinical Cancer Research, 2008
- Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2006
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005